No Data
No Data
Huapont Life Sciences (002004.SZ): As of August 9, 2024, the company has 79,239 shareholders.
On August 13th, Gelonhui reported that as of August 9th, 2024, the number of shareholders of Huapont Life Sciences (002004.SZ) was 79,239.
Huapont Life Sciences (002004.SZ): Both Purejin and Puxin Biotech are companies in which the company has invested.
Huapont Life Sciences (002004.SZ) said on the investor communication platform on August 9th that Puruijin and Pusen Biology are both companies in which the company holds shares. Puruijin is mainly engaged in the research and development of innovative drugs for cell and gene therapy. Currently, the company holds a total of 13.19% of its equity through direct and indirect means; Pusen Biology is mainly engaged in the CDMO business of cell and gene therapy drugs, and the company currently holds 8.99% of its equity. If the company has any further shareholding plans in the future, it will strictly fulfill its information disclosure obligations in a timely manner in accordance with relevant requirements.
Huapont Life Sciences (002004.SZ): has repurchased 0.35% of its shares in total.
On August 1st, Gelunhui reported that Huapont Life Sciences (002004.SZ) accumulated repurchased 6,959,908 shares of the company through centralized trading as of July 31, 2024, accounting for 0.35% of the total share capital. The highest fill price is CNY 4.65/share, the lowest fill price is CNY 3.84/share, and the total amount paid is CNY 29,499,256.13 (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
There Are Reasons To Feel Uneasy About Huapont Life SciencesLtd's (SZSE:002004) Returns On Capital
Huapont Life Sciences (002004.SZ): The specific timetable for Hanjiang Pharmaceutical's listing has not yet been determined.
On July 16th, Huapont Life Sciences (002004.SZ) stated on the investor interaction platform that Hanjiang Pharmaceutical is a subsidiary of the company, mainly engaged in the research and development, production, and sales of pharmaceutical active ingredients and intermediates, covering products such as corticosteroids, anthelmintic, respiratory system, and digestive system, and has established long-term cooperation relationships with internationally renowned pharmaceutical companies such as Abbott Laboratories, Johnson & Johnson, Eli Lilly and Co, and Merck. The specific timetable for the listing of Hanjiang Pharmaceuticals has not yet been determined, but Hanjiang Pharmaceuticals has the possibility of being listed based on its business and operating performance, and the specific situation should be based on the company's announcement information.
Huapont Life Sciences (002004.SZ): As of July 10th, the number of shareholders in the company is 79,950.
On July 16th, Gelunhui reported that as of July 10, 2024, the number of shareholders in Huapont Life Sciences (002004.SZ) was 79950.
No Data